Reduced blood pressure and increased sensitivity of the vasculature to parathyroid hormone-related protein (PTHrP) in transgenic mice overexpressing the PTH/PTHrP receptor in vascular smooth muscle. 1999

J Qian, and J N Lorenz, and S Maeda, and R L Sutliff, and C Weber, and T Nakayama, and M C Colbert, and R J Paul, and J A Fagin, and T L Clemens
Department of Medicine, University of Cincinnati, Ohio 45267-0547, USA.

PTH-related protein (PTHrP) is produced in vascular smooth muscle, where it is postulated to exert vasorelaxant properties by activation of the PTH/PTHrP type 1 receptor. As a model for studying the actions of locally produced PTHrP in vascular smooth muscle in vivo, we developed transgenic mice that overexpress the PTH/PTHrP receptor (PTHrP-R) in smooth muscle. Oocyte injection with a SMP8-PTHrP-R fusion construct yielded six founder mice. F1 offspring were viable and demonstrated selective overexpression of the SMP8-PTHP-R messenger RNA in smooth muscle-rich tissues. Baseline blood pressure measured in conscious mice by tail sphygmomanometry was significantly lower in the receptor-overexpressing mice than that in controls (117 +/- 4 vs. 133 +/- 3 mm Hg; P < 0.05). In anesthetized animals, iv infusion of PTHrP-(1-34)NH2 caused a significantly greater reduction in blood pressure and total peripheral resistance in transgenic mice than in control animals. Vascular contractility was studied in paired, isometrically mounted aortas from 9-week-old transgenic and wild-type mice. The force of contraction in response to phenlyephrine was not significantly different between transgenic and wild-type mice. However, PTHrP-(1-34) NH2 relaxed aortic vessel preparations from transgenic mice to a greater extent than in controls (77.1 +/- 3% vs. 38.4 +/- 4%; P < 0.001). To determine the impact of overexpression of PTH/PTHrP type 1 receptor and its ligand on the development of the cardiovascular system, double transgenic mice were created by crossing SMP8-PTHrP-R transgenic mice with mice overexpressing PTHrP (SMP8-PTHrP). Double transgenic mice died around day E9 with abnormalities in the developing heart. In conclusion, overexpression of PTH/PTHrP type 1 receptor in vascular smooth muscle of transgenic mice reduces blood pressure, probably through sustained activation of the receptor by endogenous ligand. The cardiovascular defects observed in mice overexpressing both PTHrP and its receptor suggest that PTHrP may play a role in the normal development of the cardiovascular system.

UI MeSH Term Description Entries
D008822 Mice, Transgenic Laboratory mice that have been produced from a genetically manipulated EGG or EMBRYO, MAMMALIAN. Transgenic Mice,Founder Mice, Transgenic,Mouse, Founder, Transgenic,Mouse, Transgenic,Mice, Transgenic Founder,Transgenic Founder Mice,Transgenic Mouse
D009119 Muscle Contraction A process leading to shortening and/or development of tension in muscle tissue. Muscle contraction occurs by a sliding filament mechanism whereby actin filaments slide inward among the myosin filaments. Inotropism,Muscular Contraction,Contraction, Muscle,Contraction, Muscular,Contractions, Muscle,Contractions, Muscular,Inotropisms,Muscle Contractions,Muscular Contractions
D009131 Muscle, Smooth, Vascular The nonstriated involuntary muscle tissue of blood vessels. Vascular Smooth Muscle,Muscle, Vascular Smooth,Muscles, Vascular Smooth,Smooth Muscle, Vascular,Smooth Muscles, Vascular,Vascular Smooth Muscles
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D010656 Phenylephrine An alpha-1 adrenergic agonist used as a mydriatic, nasal decongestant, and cardiotonic agent. (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol,Metaoxedrin,Metasympatol,Mezaton,Neo-Synephrine,Neosynephrine,Phenylephrine Hydrochloride,Phenylephrine Tannate,Neo Synephrine,Tannate, Phenylephrine
D011506 Proteins Linear POLYPEPTIDES that are synthesized on RIBOSOMES and may be further modified, crosslinked, cleaved, or assembled into complex proteins with several subunits. The specific sequence of AMINO ACIDS determines the shape the polypeptide will take, during PROTEIN FOLDING, and the function of the protein. Gene Products, Protein,Gene Proteins,Protein,Protein Gene Products,Proteins, Gene
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D000199 Actins Filamentous proteins that are the main constituent of the thin filaments of muscle fibers. The filaments (known also as filamentous or F-actin) can be dissociated into their globular subunits; each subunit is composed of a single polypeptide 375 amino acids long. This is known as globular or G-actin. In conjunction with MYOSINS, actin is responsible for the contraction and relaxation of muscle. F-Actin,G-Actin,Actin,Isoactin,N-Actin,alpha-Actin,alpha-Isoactin,beta-Actin,gamma-Actin,F Actin,G Actin,N Actin,alpha Actin,alpha Isoactin,beta Actin,gamma Actin

Related Publications

J Qian, and J N Lorenz, and S Maeda, and R L Sutliff, and C Weber, and T Nakayama, and M C Colbert, and R J Paul, and J A Fagin, and T L Clemens
January 1998, Critical reviews in eukaryotic gene expression,
J Qian, and J N Lorenz, and S Maeda, and R L Sutliff, and C Weber, and T Nakayama, and M C Colbert, and R J Paul, and J A Fagin, and T L Clemens
October 2005, Nihon rinsho. Japanese journal of clinical medicine,
J Qian, and J N Lorenz, and S Maeda, and R L Sutliff, and C Weber, and T Nakayama, and M C Colbert, and R J Paul, and J A Fagin, and T L Clemens
January 2008, Molecular endocrinology (Baltimore, Md.),
J Qian, and J N Lorenz, and S Maeda, and R L Sutliff, and C Weber, and T Nakayama, and M C Colbert, and R J Paul, and J A Fagin, and T L Clemens
August 1996, Endocrinology,
J Qian, and J N Lorenz, and S Maeda, and R L Sutliff, and C Weber, and T Nakayama, and M C Colbert, and R J Paul, and J A Fagin, and T L Clemens
October 2005, Nihon rinsho. Japanese journal of clinical medicine,
J Qian, and J N Lorenz, and S Maeda, and R L Sutliff, and C Weber, and T Nakayama, and M C Colbert, and R J Paul, and J A Fagin, and T L Clemens
April 1996, Nihon rinsho. Japanese journal of clinical medicine,
J Qian, and J N Lorenz, and S Maeda, and R L Sutliff, and C Weber, and T Nakayama, and M C Colbert, and R J Paul, and J A Fagin, and T L Clemens
February 2004, Scandinavian journal of gastroenterology,
J Qian, and J N Lorenz, and S Maeda, and R L Sutliff, and C Weber, and T Nakayama, and M C Colbert, and R J Paul, and J A Fagin, and T L Clemens
October 1999, Archives of oral biology,
J Qian, and J N Lorenz, and S Maeda, and R L Sutliff, and C Weber, and T Nakayama, and M C Colbert, and R J Paul, and J A Fagin, and T L Clemens
September 1994, Endocrinology,
J Qian, and J N Lorenz, and S Maeda, and R L Sutliff, and C Weber, and T Nakayama, and M C Colbert, and R J Paul, and J A Fagin, and T L Clemens
November 2000, Biopolymers,
Copied contents to your clipboard!